{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"CR with MRD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"CRi"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Cytoreduction"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Number of patients who achieved a Complete Response (CR) with Minimal Residual Disease (MRD), a Complete Response with incomplete hematologic recovery (CRi), or showed reduced blasts in their bone marrow by flow cytometry (Cytoreduction).\n\nCheson et al. defines a CR as: Bone Marrow blasts \\<5%, absence of circulating blasts and blasts with Auer rods, absence of extramedullary disease, absolute neutrophil count \\>1.0 x 10\\^9/L, and platelet count \\>100 x 10\\^9/L. Cheson et al. defines a CRi as: all CR criteria except for residual neutropenia (\\<1.0 x 10\\^9/L) or thrombocytopenia (\\<100 x 10\\^9/L).","groups":[{"id":"OG000","title":"Treated Patients"}],"paramType":"NUMBER","populationDescription":"14 patients received therapy. Out of 14 patients treated, 9 were evaluable (4 patients died prior to D14-21 marrow and 1 patient refused the D14-21 marrow).","reportingStatus":"POSTED","timeFrame":"Baseline up to 2 years","title":"Rate of Complete Response, Defined by Criteria of Cheson et al.","type":"SECONDARY","unitOfMeasure":"Patients"}